
Third-quarter sales rose 4%, while Novartis lifted its full-year outlook for core operating income growth to flat to low single digits.
Novartis raised its 2026 outlook for core operating income after third-quarter net sales climbed 4% to $14.5 billion. Core operating income increased 10% at constant currencies to $6.0 billion.
The company now expects full-year core operating income to be flat to up by a low single-digit percentage, versus its previous forecast of a low single-digit decline. Its outlook for net sales growth remains in the low single digits.
The core operating margin reached 41.6%, up 2 percentage points at constant currencies. Core earnings per share rose 8% at constant currencies to $2.46.
Reported operating income fell 61% at constant currencies, mainly because of a $1.9 billion partial impairment tied to the Del-Desiran research project. Net income dropped 71% on the same basis to $1.2 billion.
Novartis shares traded at CHF 129.24, up 1.38% from the previous close, as of 08:23 UTC on Tuesday.
This article was produced with the help of AI technology. Based on reporting by the outlets listed above.